Winton Group LTD Reata Pharmaceuticals Inc Transaction History

Winton Group LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$30.85 - $93.17 $57,535 - $173,762	1,865 Added 20.68%	10,882 $989,000
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $7,331 - $13,938	331 Added 3.81%	9,017 $342,000
Q3 2022 Nov 10, 2022	SELL	$19.41 - $36.49 $21,972 - $41,306	-1,132 Reduced 11.53%	8,686 $218,000
Q2 2022 Aug 10, 2022	SELL	$20.71 - $36.5 $134,822 - $237,615	-6,510 Reduced 39.87%	9,818 $298,000
Q1 2022 May 11, 2022	BUY	$24.12 - $39.6 $393,831 - $646,588	16,328 New	16,328 $535,000
Q3 2021 Oct 28, 2021	SELL	$100.0 - $143.02 $273,300 - $390,873	-2,733 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$78.27 - $151.29 $188,161 - $363,701	-2,404 Reduced 46.8%	2,733 $387,000
Q1 2021 Jul 21, 2021	BUY	$94.25 - $132.81 $69,933 - $98,545	742 Added 16.88%	5,137 $512,000
Q4 2020 Feb 12, 2021	SELL	$102.03 - $184.62 $869,907 - $1.57 Million	-8,526 Reduced 65.99%	4,395 $543,000
Q3 2020 Oct 30, 2020	BUY	$93.53 - $163.34 $1.21 Million - $2.11 Million	12,921 New	12,921 $1.26 Million
Q2 2019 Jul 08, 2019	SELL	$77.72 - $94.35 $185,439 - $225,119	-2,386 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$51.9 - $101.79 $123,833 - $242,870	2,386 New	2,386 $204,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.